Loading
Once a patient has safely had the first few doses of a trial drug at the hospital, later doses could be given at home or a local clinic, with blood tests done nearby, so distance no longer decides who can join.
Protocols pre-specify a decentralised phase: after two or three supervised cycles, eligible patients receive subcutaneous or infused trial drug via home-infusion nursing or a local clinic under the site investigator's oversight, with labs at community draw stations, ePRO-based toxicity capture and telehealth visits. Pandemic-era regulatory flexibilities showed feasibility; the idea is to write it into protocols by default for drugs with predictable safety.
Shares Trastuzumab, Nivolumab, Monoclonal antibodies, Pembrolizumab.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/